J. D. Wolchok, V. Chiarion-sileni, R. Gonzalez, P. Rutkowski, J. Grob et al., Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.377, pp.1345-1356, 2017.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, pp.1823-1833, 2016.

A. Hauschild, J. Grob, L. V. Demidov, T. Jouary, R. Gutzmer et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, pp.358-365, 2012.

E. Bronte, G. Bronte, G. Novo, G. Rinaldi, F. Bronte et al., Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors, Pharmacology & Therapeutics, 2018.

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, pp.2507-2516, 2011.

P. Chen, F. Chen, and B. Zhou, Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis, OncoTargets and Therapy, vol.10, pp.5391-5403, 2017.

S. Pasquali, A. V. Hadjinicolaou, C. Sileni, V. Rossi, C. R. Mocellin et al., Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews, 2018.

J. R. Infante, B. G. Somer, J. O. Park, C. Li, M. E. Scheulen et al., A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas, European Journal of Cancer, vol.50, pp.2072-2081, 2014.

J. Larkin, P. A. Ascierto, B. Dreno, V. Atkinson, G. Liszkay et al., Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, vol.371, pp.1867-1876, 2014.

M. Maio, K. Lewis, L. Demidov, M. Mandalà, I. Bondarenko et al., Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebocontrolled, multicentre, Lancet Oncol, vol.19, pp.510-520, 2018.

O. Abdel-rahman, H. Elhalawani, and H. Ahmed, Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis, J Glob Oncol, vol.1, pp.73-82, 2015.

L. Shamseer, D. Moher, M. Clarke, D. Ghersi, A. Liberati et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation, BMJ, vol.350, p.7647, 2015.

, Cochrane Handbook for Systematic Reviews of Interventions, 2018.

M. Liu, X. Yang, J. Liu, B. Zhao, W. Cai et al., Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials, Oncotarget, vol.8, pp.32258-32269, 2017.

Y. Yang, Y. Liu, X. Sun, M. Yu, L. Yang et al., Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials, Curr Med Res Opin, vol.33, pp.1663-1675, 2017.

P. Mozzicato, Standardised MedDRA Queries. Drug-Safety, vol.30, pp.617-619, 2007.

. Commissioner-o-of-the, Reporting Serious Problems to FDA -What is a Serious Adverse Event?, 2018.

J. Higgins, D. G. Altman, P. C. Gøtzsche, P. Jüni, D. Moher et al., Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, vol.343, p.5928, 2011.

, GRADE home, 2009.

R. D. Carvajal, S. Piperno-neumann, E. Kapiteijn, P. B. Chapman, S. Frank et al., Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT), J Clin Oncol, 2018.

P. A. Janne, A. T. Shaw, J. R. Pereira, G. Jeannin, J. Vansteenkiste et al., Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study, Lancet Oncol, vol.14, pp.38-47, 2013.

P. A. Janne, M. M. Van-den-heuvel, F. Barlesi, M. Cobo, J. Mazieres et al., Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The, JAMA, vol.317, pp.1844-1853, 2017.

C. Robert, R. Dummer, R. Gutzmer, P. Lorigan, K. B. Kim et al., Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study, The Lancet Oncology, vol.14, pp.733-740, 2013.

J. Soria, A. Fulop, C. Maciel, J. R. Fischer, G. Girotto et al., SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer, Ann Oncol, vol.28, pp.3028-3036, 2017.

E. Van-cutsem, M. Hidalgo, J. Canon, T. Macarulla, I. Bazin et al., Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer, Int J Cancer, vol.143, pp.2053-2064, 2018.

K. Zaman, R. Winterhalder, C. Mamot, U. Hasler-strub, C. Rochlitz et al., Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08, European Journal of Cancer, vol.51, pp.1212-1220, 2015.

P. A. Ascierto, G. A. Mcarthur, B. Dréno, V. Atkinson, G. Liszkay et al., Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, The Lancet Oncology, vol.17, pp.1248-1260, 2016.

G. V. Long, K. T. Flaherty, D. Stroyakovskiy, H. Gogas, E. Levchenko et al., Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Ann Oncol, vol.28, pp.1631-1639, 2017.

B. Dreno, A. Ribas, J. Larkin, P. A. Ascierto, A. Hauschild et al., Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study, Ann Oncol, vol.28, pp.1137-1144, 2017.

S. J. Welsh and P. G. Corrie, Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma, Ther Adv Med Oncol, vol.7, pp.122-136, 2015.

Y. Zhao and A. A. Adjei, The clinical development of MEK inhibitors, Nat Rev Clin Oncol, vol.11, pp.385-400, 2014.

T. Xie, C. Huang, X. Kang, J. Luo, X. Qin et al., A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials, J Cell Biochem, vol.119, pp.640-649, 2018.

M. Franken, B. Leeneman, M. Gheorghe, N. Buyukkaramikli, J. Gerrits et al., Comparative Effectiveness Of Novel Treatments For Advanced Melanoma: A Systematic Literature Review And Network Meta-Analysis Of Effectiveness And Safety Outcomes, Value in Health, vol.20, pp.412-413, 2017.

J. L. Zamorano, P. Lancellotti, R. Muñoz, D. Aboyans, V. Asteggiano et al., ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments, Eur Heart J, vol.37, pp.2768-2801, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01788726

, Supplementary Figure 1 -Funnel plots of log odds-ratio standard error by odds-ratio to evaluate publication bias for the primary outcomes (A) all-grade hypertension, (B) all-grade ejection fraction decrease and (C) all-grade peripheral oedema in monotherapy trials Supplementary Data 1 (appendix 1) -Draft MEDLINE search with High sensitivity filter for randomized clinical trials -Ovid interface 1

. Cobimetinib,

O. R. Trametinib and . Gsk,

. Selumetinib,

. Pimasertib,

. Vemurafenib,

O. Dabrafenib and . Gsk,

. Encorafenib,